JP2025508746A5 - - Google Patents
Info
- Publication number
- JP2025508746A5 JP2025508746A5 JP2024548633A JP2024548633A JP2025508746A5 JP 2025508746 A5 JP2025508746 A5 JP 2025508746A5 JP 2024548633 A JP2024548633 A JP 2024548633A JP 2024548633 A JP2024548633 A JP 2024548633A JP 2025508746 A5 JP2025508746 A5 JP 2025508746A5
- Authority
- JP
- Japan
- Prior art keywords
- characteristic peaks
- exhibits
- crystal morphology
- group
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311869P | 2022-02-18 | 2022-02-18 | |
| US63/311,869 | 2022-02-18 | ||
| PCT/US2023/012898 WO2023158607A1 (en) | 2022-02-18 | 2023-02-13 | Polymorphic forms and methods of producing polymorphic forms of a compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508746A JP2025508746A (ja) | 2025-04-10 |
| JP2025508746A5 true JP2025508746A5 (https=) | 2026-02-24 |
Family
ID=87578977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024548633A Pending JP2025508746A (ja) | 2022-02-18 | 2023-02-13 | 化合物の多形形態及び多形形態を生成する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250034183A1 (https=) |
| EP (1) | EP4479409A4 (https=) |
| JP (1) | JP2025508746A (https=) |
| KR (1) | KR20240152889A (https=) |
| CN (1) | CN119053613A (https=) |
| AU (1) | AU2023221889A1 (https=) |
| CA (1) | CA3252569A1 (https=) |
| MX (1) | MX2024010008A (https=) |
| WO (1) | WO2023158607A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1882327A (zh) * | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| EP1891080A2 (en) * | 2005-05-26 | 2008-02-27 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| WO2006128056A2 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| WO2020117962A1 (en) * | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
-
2023
- 2023-02-13 JP JP2024548633A patent/JP2025508746A/ja active Pending
- 2023-02-13 EP EP23756786.2A patent/EP4479409A4/en active Pending
- 2023-02-13 KR KR1020247031018A patent/KR20240152889A/ko active Pending
- 2023-02-13 MX MX2024010008A patent/MX2024010008A/es unknown
- 2023-02-13 CN CN202380034735.3A patent/CN119053613A/zh active Pending
- 2023-02-13 WO PCT/US2023/012898 patent/WO2023158607A1/en not_active Ceased
- 2023-02-13 US US18/836,713 patent/US20250034183A1/en active Pending
- 2023-02-13 AU AU2023221889A patent/AU2023221889A1/en active Pending
- 2023-02-13 CA CA3252569A patent/CA3252569A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508746A5 (https=) | ||
| JP2023504643A5 (https=) | ||
| JP2024500309A5 (https=) | ||
| JP2024520677A5 (https=) | ||
| JP2023002662A5 (https=) | ||
| JP2015522616A5 (https=) | ||
| JP5596799B2 (ja) | カナグリフロジン含有錠剤 | |
| JP2018507914A5 (https=) | ||
| JP2023537285A5 (https=) | ||
| RU2017114109A (ru) | Кристаллические модификации элобиксибата | |
| JP2023504644A5 (https=) | ||
| JP2023546125A5 (https=) | ||
| JP2018518537A5 (https=) | ||
| JP2024516371A5 (https=) | ||
| RU2015150039A (ru) | Кристаллическая модификация | |
| JP2023504647A5 (https=) | ||
| TW200829259A (en) | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate | |
| WO2016131414A1 (zh) | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 | |
| HRP20240265T1 (hr) | Spoj izoksazola kao fxr agonist i farmaceutski pripravci koji ga sadrže | |
| JP2013502442A5 (https=) | ||
| IL297844A (en) | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids | |
| JP2022031813A (ja) | １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| JP2023502005A5 (https=) | ||
| JP2012519714A (ja) | トライアシル−３−ヒドロキシフェニルアデノシン及びその血中脂肪の調節用途 | |
| JP2024541569A5 (https=) |